Hysteroscopic Tissue Removal System Versus Bipolar Resectoscopy for Polypectomy: Long-term Results

Sponsor
University Hospital, Ghent (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05337046
Collaborator
(none)
84
1
9
9.3

Study Details

Study Description

Brief Summary

In this study, a comparison is made between two types of polyp resection methods (hysteroscopic tissue removal and bipolar resectoscopy). More specifically, the effects of the resection on symptoms such as abnormal uterine bleeding, and on the recurrence of polyps. The aim of the study is to find a superior method in terms of symptom relieve and polyp recurrence so this method can be used in gynaecological practice.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    • Rationale: Several techniques for hysteroscopic removal of intrauterine polyps exist today. Up until the first decade of this century, larger polyps were usually removed via bipolar resectoscopy. Later, the hysteroscopic tissue removal system (morcellation) was introduced in which the abnormal tissue is mechanically removed, which is then immediately aspirated. Previous studies comparing bipolar resection and morcellation show that this is an effective, fast, and safe method without major complications. However, the long-term results are still largely unknown.

    • Research question/goal: To investigate the long-term results of the effectiveness of hysteroscopic removal of intrauterine polyps. Bipolar resection and morcellation are compared here.

    • Study design: This is a prospective cohort study. The patients previously participated in a randomized study (2011-2014) and will now be contacted again for the completion of a one-time questionnaire. The study has an observational design.

    • Study population: Women with a history of endometrial polyp that was previously removed via hysteroscopic morcellation in a previous study.

    • Primary and secondary endpoints: The primary endpoint is the risk of recurrence of abnormal uterine bleeding at post-surgery follow-up. Secondary endpoints include recurrence of other symptoms, time to recurrence, symptom relief, onset of new symptoms, onset of new polyp, satisfaction with regards to symptoms, satisfaction with regards to the treatment in general, need for additional treatments for blood loss and occurrence of pregnancy (in subfertility group).

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    84 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Hysteroscopic Tissue Removal System Versus Bipolar Resectoscopy for Polypectomy: Long-term Results
    Anticipated Study Start Date :
    Apr 1, 2022
    Anticipated Primary Completion Date :
    Jul 1, 2022
    Anticipated Study Completion Date :
    Jan 1, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    Tissue removal system

    Endometrial polyp removed by hysteroscopic tissue removal system in a previous study.

    Bipolar resectoscopy

    Endometrial polyp removed by hysteroscopic bipolar resectoscopy in a previous study.

    Outcome Measures

    Primary Outcome Measures

    1. Rate of recurrence of abnormal uterine blood loss (+ cause, treatment) [8 to 10 years]

      Patient reported outcome by means of a questionnaire (yes/no, specify)

    Secondary Outcome Measures

    1. Rate of recurrence of other symptoms (abdominal pain, infections, back pain, other..) (+ cause, treatment) [8 to 10 years]

      Patient reported outcome by means of a questionnaire (yes/no, specify)

    2. Recurrence interval (time to recurrence of endometrial polyp) [8 to 10 years]

      Patient reported outcome by means of a questionnaire (when did blood loss occur / when was polyp identified)

    3. Number of patients with symptom relief after initial intervention (abdominal pain, abnormal uterine blood loss, other...) [8 to 10 years]

      Patient reported outcome by means of a questionnaire

    4. Rate of occurrence of new symptoms after initial intervention (abdominal pain, abnormal uterine blood loss, infections, other...) (+ cause, treatment) [8 to 10 years]

      Patient reported outcome by means of a questionnaire (yes/no, specify)

    5. Rate of occurrence of new polyps (+ cause, treatment) [8 to 10 years]

      Patient reported outcome by means of a questionnaire (yes/no, specify)

    6. Satisfaction score in regard to symptoms (abdominal pain, abnormal uterine blood loss, other...) [8 to 10 years]

      Patient reported outcome by means of a questionnaire on a scale from 0 (bad) to 5 (great)

    7. General satisfaction score in regard to initial treatment [8 to 10 years]

      Patient reported outcome by means of a questionnaire on a scale from 0 (bad) to 5 (great)

    8. Rate of need for additional treatment [8 to 10 years]

      Patient reported outcome by means of a questionnaire (yes/no, specify)

    9. Chance of pregnancy after treatment [8 to 10 years]

      Only applicable for women with fertility problems, Patient reported outcome by means of a questionnaire.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • participation in earlier study
    Exclusion Criteria:
    • N/A

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Catharina ziekenhuis Eindhoven Noord-Brabant Netherlands 5623 EJ

    Sponsors and Collaborators

    • University Hospital, Ghent

    Investigators

    • Principal Investigator: Tjalina Hamerlynck, Md, Phd, University Hospital, Ghent

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Ghent
    ClinicalTrials.gov Identifier:
    NCT05337046
    Other Study ID Numbers:
    • BC-11629 BC-11630 BC-11631
    First Posted:
    Apr 20, 2022
    Last Update Posted:
    Apr 20, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Apr 20, 2022